Back to search
Cancer Risk
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Cancer Risk trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Cancer Risk trials you may qualify forThis non-interventional observational study evaluates the real-world effectiveness and safety profile of ribociclib in combination with an aromatase inhibitor f…
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast…
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy)…
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (…
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with hig…
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or…
The purpose of this single arm, open label study is to evaluate the feasibility of pembrolizumab combined with radiation administered to the upper part of the v…
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with…
The main objective of the study is to measure adherence to a lung cancer screening program using low-dose thoracic CT.